Back to News
Market Impact: 0.25
Ligand Commits Upto $47 Mln To AvenCell Cancer Cell Therapy
Source: Nasdaq
Healthcare & BiotechPrivate Markets & VentureCompany Fundamentals
Ligand Pharmaceuticals announced a financing agreement with clinical-stage cell therapy company AvenCell Therapeutics worth up to $47 million. The funding is intended to advance AvenCell's pipeline, including AVC-201 for relapsed/refractory disease, although the article excerpt does not provide further clinical, financial, or milestone terms.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
LGND0.45
More News
- Oracle Japan shares surge 7% after record fiscal first quarter, bucking selloff of U.S. parent
- Akamai secures $11.6B cloud deal with Anthropic for AI workloads
- Costco makes progress on a key membership metric. Here's our new price target on the stock
- Here’s the Tesla Semi… again
- Why we like Starbucks’ latest turnaround move — plus, two more wins for Eli Lilly
- OpenAI says agent hacked Australian government website without being told to do so
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market
- Investment Research Software Costs: A 2026 Budget Framework